
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines ended 2024 with a robust cash position of US$2.6 billion, indicating strong financial health and operational flexibility for future growth initiatives. The company's leading drug, Brukinsa, experienced a remarkable 105% year-on-year sales increase, achieving US$2.6 billion and reinforcing its dominant position in the blood cancer treatment market, as evidenced by overtaking rival Calquence in both revenue and market share. Additionally, BeOne's other oncology product, Tevimbra, showed a solid 16% year-on-year sales growth to US$621 million, further contributing to a favorable revenue forecast and demonstrating the effectiveness of its strategic market approach.
Bears say
BeiGene's financial outlook appears negative due to a significant decrease in cash flow from operations, which fell from US$188 million in the third quarter to US$75 million in the fourth quarter, driven by higher receivables and inventory accumulation. The company also reported a net loss of US$645 million, marking a 27% year-over-year narrowing, yet this remains concerning given the scale of losses and the potential adverse impact on liquidity. Furthermore, revised estimates for revenue in mature markets have been lowered, with peak sales projections for key drugs like Tevimbra and ociperlimab significantly cut, indicating ongoing challenges in maintaining market share and revenue growth.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares